Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07236190 · ClinicalTrials.gov registry record · Phase 2
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07236190: Recruiting Phase 2 study, sponsored by Massachusetts General Hospital.
NCT07236190 is a Phase 2 study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07236190, a Phase 2 study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology
Interventions
- COMBINATION_PRODUCT natural product combination-1 (NPC1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07236190
The ClinicalTrials.gov registry entry for NCT07236190 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which natural product combination-1 (NPC1) is the first listed.
NCT07236190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07236190 about?
NCT07236190 is a clinical study titled "Biomarker-based Trial of NPC-1 for Alzheimer's Pathology". This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment...
What is the current status of trial NCT07236190?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-04-01. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07236190?
The interventions under investigation include: natural product combination-1 (NPC1) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07236190?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.